{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:43:02Z","timestamp":1791546182522,"version":"4.3.4"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiac amyloidosis (CA) is a progressive, underdiagnosed condition caused by the deposition of misfolded proteins in the myocardium, forming amyloid fibrils that impair cardiac structure and function. This review highlights recent advances in the diagnosis and treatment of amyloid light-chain (AL) and transthyretin (ATTR) CA, which globally account for most cases of CA. Novel diagnostic tools, including artificial intelligence-enhanced analysis and advanced imaging modalities like positron emission tomography with amyloid-specific tracers, might improve detection rates and diagnostic accuracy to enable non-invasive subtype differentiation. Furthermore, many innovative treatments are being investigated. For AL-CA, anti-fibril therapies are showing promising results, complementing traditional chemotherapy and autologous stem cell transplantation. In ATTR-CA, gene silencing and anti-fibril therapies are being tested in clinical trials and hold promise of halting disease progression and reducing amyloid deposits, respectively.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suae111","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T07:16:32Z","timestamp":1732950992000},"page":"i88-i97","source":"Crossref","is-referenced-by-count":13,"title":["Cardiac amyloidosis: Innovations in diagnosis and treatment"],"prefix":"10.1093","volume":"27","author":[{"given":"Vincenzo","family":"Castiglione","sequence":"first","affiliation":[{"name":"Health Science Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]},{"name":"Cardio-thoracic Department, Fondazione Toscana Gabriele Monasterio , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Montuoro","sequence":"additional","affiliation":[{"name":"Health Science Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Orlando","sequence":"additional","affiliation":[{"name":"Health Science Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[{"name":"Health Science Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]},{"name":"Cardio-thoracic Department, Fondazione Toscana Gabriele Monasterio , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[{"name":"Health Science Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]},{"name":"Cardio-thoracic Department, Fondazione Toscana Gabriele Monasterio , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8541-1962","authenticated-orcid":false,"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[{"name":"Health Science Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]},{"name":"Cardio-thoracic Department, Fondazione Toscana Gabriele Monasterio , Via Giuseppe Moruzzi 1, Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2025021911172111100_suae111-B1","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2025021911172111100_suae111-B2","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2025021911172111100_suae111-B3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00259-010-1642-7","article-title":"Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy.","volume":"38","author":"Rapezzi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025021911172111100_suae111-B4","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2025021911172111100_suae111-B5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"2025021911172111100_suae111-B6","first-page":"59","article-title":"Serum and tissue light-chains as disease biomarkers and targets for treatment in AL amyloidosis","volume":"6","author":"Camerini","year":"2022","journal-title":"Vessel Plus"},{"key":"2025021911172111100_suae111-B7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)","volume":"110","author":"Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2025021911172111100_suae111-B8","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2025021911172111100_suae111-B9","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka","year":"2020","journal-title":"Circ J"},{"key":"2025021911172111100_suae111-B10","first-page":"e7","article-title":"American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2021","journal-title":"Circulation"},{"key":"2025021911172111100_suae111-B11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cjca.2019.11.036","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O\u2019Meara","year":"2020","journal-title":"Can J Cardiol"},{"key":"2025021911172111100_suae111-B12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/heartjnl-2013-304957","article-title":"High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis","volume":"100","author":"Dispenzieri","year":"2014","journal-title":"Heart"},{"key":"2025021911172111100_suae111-B13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025021911172111100_suae111-B14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B15","doi-asserted-by":"crossref","first-page":"e13449","DOI":"10.1111\/eci.13449","article-title":"A simple echocardiographic score to rule out cardiac amyloidosis","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2025021911172111100_suae111-B16","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1002\/ejhf.2616","article-title":"Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025021911172111100_suae111-B17","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025021911172111100_suae111-B18","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3455","article-title":"The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis","author":"Bonfioli","journal-title":"Eur J Heart Fail"},{"key":"2025021911172111100_suae111-B19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ehjci\/jeac057","article-title":"Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B20","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"2025021911172111100_suae111-B21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ehjci\/jey225","article-title":"Mechanisms of heart failure in transthyretin vs. light chain amyloidosis","volume":"20","author":"Binder","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jcmg.2020.08.035","article-title":"Left ventricular mass-to-strain ratio predicts cardiac amyloid subtype","volume":"14","author":"Geenty","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B23","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.jcmg.2021.05.029","article-title":"The left ventricular mass-to-strain ratio: enough to differentiate ATTR from AL cardiac amyloidosis?","volume":"14","author":"Aimo","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B24","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2025021911172111100_suae111-B25","first-page":"101167","article-title":"CMR-based right ventricular strain analysis in cardiac amyloidosis and its potential as a supportive diagnostic feature","volume":"44","author":"Eckstein","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2025021911172111100_suae111-B26","doi-asserted-by":"crossref","first-page":"e009901","DOI":"10.1161\/CIRCIMAGING.119.009901","article-title":"Diffusion tensor cardiovascular magnetic resonance in cardiac amyloidosis","volume":"13","author":"Khalique","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12350-017-0922-z","article-title":"Accuracy of 99mTc-hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis","volume":"26","author":"Cappelli","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2025021911172111100_suae111-B28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11886-020-01284-3","article-title":"Advances in PET-based cardiac amyloid radiotracers","volume":"22","author":"Gallegos","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2025021911172111100_suae111-B29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12350-021-02524-x","article-title":"Positron emission tomography for cardiac amyloidosis: timing matters!","volume":"29","author":"Singh","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2025021911172111100_suae111-B30","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","article-title":"Diagnostic accuracy of [11C]PIB positron emission tomography for detection of cardiac amyloidosis","volume":"13","author":"Rosengren","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B31","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.1021\/jm900871v","article-title":"Synthesis and evaluation of three 18F-labeled aminophenylbenzothiazoles as amyloid imaging agents","volume":"52","author":"Serdons","year":"2009","journal-title":"J Med Chem"},{"key":"2025021911172111100_suae111-B32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00259-015-3208-1","article-title":"Imaging \u03b2-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis","volume":"43","author":"Heurling","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025021911172111100_suae111-B33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13506129.2022.2141623","article-title":"The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis","volume":"30","author":"Abrahamson","year":"2023","journal-title":"Amyloid"},{"key":"2025021911172111100_suae111-B34"},{"key":"2025021911172111100_suae111-B35","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMp1208061","article-title":"Brain amyloid imaging\u2014FDA approval of florbetapir F18 injection","volume":"367","author":"Yang","year":"2012","journal-title":"N Engl J Med"},{"key":"2025021911172111100_suae111-B36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-019-04516-z","article-title":"Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol, 11C-MeDAS, and 11C-PiB","volume":"47","author":"Auvity","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025021911172111100_suae111-B37","doi-asserted-by":"crossref","first-page":"e002954","DOI":"10.1161\/CIRCIMAGING.114.002954","article-title":"18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study","volume":"8","author":"Park","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B38","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025021911172111100_suae111-B39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jcmg.2024.05.002","article-title":"Prognostic value of left ventricular 18F-florbetapir uptake in systemic light-chain amyloidosis","volume":"17","author":"Clerc","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B40","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ehjci\/jead350","article-title":"Quantification of right ventricular amyloid burden with 18F-florbetapir positron emission tomography\/computed tomography and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis","volume":"25","author":"Datar","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18F]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B42"},{"key":"2025021911172111100_suae111-B43"},{"key":"2025021911172111100_suae111-B44","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s12350-017-0799-x","article-title":"18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis","volume":"25","author":"Morgenstern","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"2025021911172111100_suae111-B45","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s12350-020-02425-5","article-title":"Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-pyrophosphate in cardiac amyloidosis","volume":"29","author":"Zhang","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2025021911172111100_suae111-B46","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using 124I-evuzamitide (124I-P5+14) versus 18F-florbetapir","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025021911172111100_suae111-B47","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis","volume":"96","author":"Grogan","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2025021911172111100_suae111-B48","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.118.034338","article-title":"Fully automated echocardiogram interpretation in clinical practice: feasibility and diagnostic accuracy","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"2025021911172111100_suae111-B49","doi-asserted-by":"crossref","first-page":"23596","DOI":"10.1038\/s41598-021-02971-z","article-title":"Machine learning of native T1 mapping radiomics for classification of hypertrophic cardiomyopathy phenotypes","volume":"11","author":"Antonopoulos","year":"2021","journal-title":"Sci Rep"},{"key":"2025021911172111100_suae111-B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10278-024-01275-8","article-title":"Automated neural architecture search for cardiac amyloidosis classification from [18F]-florbetaben PET images","author":"Bargagna","journal-title":"J Imaging Inform Med"},{"key":"2025021911172111100_suae111-B51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"2025021911172111100_suae111-B52","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025021911172111100_suae111-B53","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B54","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B55","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B56","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1002\/ajh.24464","article-title":"Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation","volume":"91","author":"Havasi","year":"2016","journal-title":"Am J Hematol"},{"key":"2025021911172111100_suae111-B57","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B58","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.25566","article-title":"Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Am J Hematol"},{"key":"2025021911172111100_suae111-B59","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2025021911172111100_suae111-B60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"},{"key":"2025021911172111100_suae111-B61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"key":"2025021911172111100_suae111-B62","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B63","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL amyloidosis: current chemotherapy and immune therapy treatment strategies","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2025021911172111100_suae111-B64","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025021911172111100_suae111-B65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11899-020-00574-5","article-title":"Updates in the diagnosis and management of AL amyloidosis","volume":"15","author":"Cook","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"2025021911172111100_suae111-B66","doi-asserted-by":"crossref","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","article-title":"Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis","volume":"25","author":"Emdin","year":"2023","journal-title":"Eur Heart J Suppl"},{"key":"2025021911172111100_suae111-B67","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40259-022-00550-w","article-title":"Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis","volume":"36","author":"Nuvolone","year":"2022","journal-title":"BioDrugs"},{"key":"2025021911172111100_suae111-B68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"2025021911172111100_suae111-B69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B70","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-143180","article-title":"A phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated AL amyloidosis (SWOG S1702; NCT#03499808)","volume":"136","author":"Parker","year":"2020","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B71","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s11864-021-00922-4","article-title":"Immunotherapy in AL amyloidosis","volume":"23","author":"Zhang","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2025021911172111100_suae111-B72","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bjh.16436","article-title":"Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits","volume":"189","author":"Popkova","year":"2020","journal-title":"Br J Haematol"},{"key":"2025021911172111100_suae111-B73","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.clml.2018.08.021","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone for treatment-resistant immunoglobulin light chain amyloidosis with multiple myeloma","volume":"19","author":"Iqbal","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025021911172111100_suae111-B74","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","article-title":"2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis","volume":"23","author":"Renz","year":"2016","journal-title":"Amyloid"},{"key":"2025021911172111100_suae111-B75","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025021911172111100_suae111-B76","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2019-124482","article-title":"Results of the phase 3 VITAL study of NEOD001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients","volume":"134","author":"Gertz","year":"2019","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B77","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B78","doi-asserted-by":"crossref","first-page":"TPS8076","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8076","article-title":"Birtamimab in patients with Mayo stage IV AL amyloidosis: rationale for confirmatory affirm-AL phase 3 study","volume":"40","author":"Gertz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025021911172111100_suae111-B79","doi-asserted-by":"crossref","first-page":"e3270","DOI":"10.1002\/hon.3270","article-title":"Novel monoclonal antibodies: a really specific therapy for light chain amyloidosis","volume":"42","author":"Del Giudice","year":"2024","journal-title":"Hematol Oncol"},{"key":"2025021911172111100_suae111-B80","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B81","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139323","article-title":"Cael-101 is well-tolerated in AL amyloidosis patients receiving concomitant cyclophosphamide-bortezomib-dexamethasone (CyborD): a phase 2 dose-finding study (NCT04304144)","volume":"136","author":"Valent","year":"2020","journal-title":"Blood"},{"key":"2025021911172111100_suae111-B82"},{"key":"2025021911172111100_suae111-B83"},{"key":"2025021911172111100_suae111-B84","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"2025021911172111100_suae111-B85","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/13506120701614032","article-title":"Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation","volume":"14","author":"Liepnieks","year":"2007","journal-title":"Amyloid"},{"key":"2025021911172111100_suae111-B86","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2025021911172111100_suae111-B87","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025021911172111100_suae111-B88","doi-asserted-by":"crossref","first-page":"ehaa946.2115","DOI":"10.1093\/ehjci\/ehaa946.2115","article-title":"Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy","volume":"41","author":"Rapezzi","year":"2020","journal-title":"Eur Heart J"},{"key":"2025021911172111100_suae111-B89","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025021911172111100_suae111-B90","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cpdd.700","article-title":"First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers","volume":"9","author":"Fox","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025021911172111100_suae111-B91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2025021911172111100_suae111-B92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2025021911172111100_suae111-B93"},{"key":"2025021911172111100_suae111-B94"},{"key":"2025021911172111100_suae111-B95","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2025021911172111100_suae111-B96","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2025021911172111100_suae111-B97","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2025021911172111100_suae111-B98"},{"key":"2025021911172111100_suae111-B99","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2025021911172111100_suae111-B100"},{"key":"2025021911172111100_suae111-B101","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"2025021911172111100_suae111-B102"},{"key":"2025021911172111100_suae111-B103","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2025021911172111100_suae111-B104","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/CRD.0000000000000387","article-title":"Transthyretin cardiac amyloidosis and novel therapies to treat this not-so-rare cause of cardiomyopathy","volume":"29","author":"Capustin","year":"2021","journal-title":"Cardiol Rev"},{"key":"2025021911172111100_suae111-B105"},{"key":"2025021911172111100_suae111-B106","author":"Novo Nordisk"},{"key":"2025021911172111100_suae111-B107","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"2025021911172111100_suae111-B108"},{"key":"2025021911172111100_suae111-B109","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/eurheartj\/ehz695","article-title":"A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model","volume":"41","author":"George","year":"2020","journal-title":"Eur Heart J"},{"key":"2025021911172111100_suae111-B110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2025021911172111100_suae111-B111","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/13506129.2021.1966624","article-title":"Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure","volume":"28","author":"Vergaro","year":"2021","journal-title":"Amyloid"},{"key":"2025021911172111100_suae111-B112","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"2025021911172111100_suae111-B113","doi-asserted-by":"crossref","first-page":"132039","DOI":"10.1016\/j.ijcard.2024.132039","article-title":"Beta-blocking patients with cardiac amyloidosis: adelante cum juicio","volume":"407","author":"Emdin","year":"2024","journal-title":"Int J Cardiol"},{"key":"2025021911172111100_suae111-B114","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_1\/i88\/61968351\/suae111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_1\/i88\/61968351\/suae111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:18:06Z","timestamp":1739945886000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/27\/Supplement_1\/i88\/8023290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":114,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,19]]},"published-print":{"date-parts":[[2025,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae111","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]}}}